Omada Health, Inc. (NASDAQ:OMDA – Get Free Report) CFO Steven Cook sold 33,000 shares of the company’s stock in a transaction dated Friday, June 26th. The stock was sold at an average price of $19.89, for a total transaction of $656,370.00. Following the transaction, the chief financial officer owned 133,359 shares in the company, valued at approximately $2,652,510.51. This trade represents a 19.84% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
Omada Health Trading Up 1.3%
OMDA traded up $0.28 during midday trading on Tuesday, hitting $21.95. The company had a trading volume of 853,685 shares, compared to its average volume of 1,070,637. Omada Health, Inc. has a twelve month low of $10.28 and a twelve month high of $26.92. The firm’s 50-day simple moving average is $16.83 and its 200-day simple moving average is $14.93.
Omada Health (NASDAQ:OMDA – Get Free Report) last announced its earnings results on Thursday, May 7th. The company reported ($0.05) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.03. Omada Health had a negative net margin of 2.22% and a negative return on equity of 1.82%. The company had revenue of $78.05 million for the quarter. As a group, equities analysts anticipate that Omada Health, Inc. will post -0.01 earnings per share for the current fiscal year.
Institutional Trading of Omada Health
Analyst Upgrades and Downgrades
A number of brokerages have commented on OMDA. JPMorgan Chase & Co. decreased their price objective on Omada Health from $32.00 to $26.00 and set an “overweight” rating on the stock in a research report on Thursday, March 12th. Wells Fargo & Company boosted their target price on Omada Health from $17.00 to $18.00 and gave the stock an “equal weight” rating in a research report on Friday, May 8th. Citigroup reaffirmed an “outperform” rating on shares of Omada Health in a research note on Friday, May 8th. The Goldman Sachs Group reiterated a “buy” rating on shares of Omada Health in a report on Friday, May 8th. Finally, Wall Street Zen raised Omada Health from a “hold” rating to a “buy” rating in a report on Saturday. Ten analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Omada Health currently has an average rating of “Moderate Buy” and an average target price of $22.91.
Read Our Latest Stock Report on Omada Health
Omada Health Company Profile
Omada Health is a digital health company that specializes in the prevention and management of chronic conditions through personalized, technology-driven programs. The company’s platform combines data analytics, behavioral science and human coaching to support individuals at risk for or living with conditions such as prediabetes, type 2 diabetes, hypertension and musculoskeletal disorders. Participants access the program via a mobile app or web portal, where they receive tailored curriculum, feedback on health metrics and ongoing virtual coaching.
In addition to its core disease-management offerings, Omada Health has expanded its services to include mental health support and digital therapeutics for weight management.
Recommended Stories
- Five stocks we like better than Omada Health
- NextEra’s Dominion Deal Could Put It at the Center of the AI Power Race
- Amazon Could Be About to Reap the Rewards of a Software Spending Boom
- Best Buy’s Turnaround Is Gaining Traction, But Wall Street Still Needs Proof
- AI Fears Hit Nebius Stock, But Has the Growth Thesis Changed?
Receive News & Ratings for Omada Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omada Health and related companies with MarketBeat.com's FREE daily email newsletter.
